Meningiomas, which account for about 40% of primary central nervous system tumors, have significant psychological and social impacts, even without treatment. Their effect on quality of life is often underestimated and poorly documented. There is one validated questionnaire (MQOL) but it has not yet been translated into French. The project involves two phases: first, translating and linguistically validating the MQOL into French; second, scientifically validating the questionnaire with 50 meningioma patients using established scales (EQ-5D, Karnofsky, FACT-Br) to ensure its reliability and internal consistency.

Inclusion Criteria:

• Patient aged 18 years or older
• Diagnosis of intracranial meningioma confirmed by imaging or surgery

Exclusion Criteria:

• Pregnant or breastfeeding women (Article L1121-5)
• Patients deprived of liberty by judicial or administrative decision, as well as individuals undergoing psychiatric care (Article L1121-6)
• Patients not fluent in French or with poor understanding of the language
• Inability to refuse participation in the study

The study population will consist of three groups to ensure maximum heterogeneity:

1. The study will be announced to all patients seen in consultation for meningioma at GHU Paris - Sainte-Anne (France).
2. All patients who are members of the AMAVEA association will be notified of the study by email.
3. Any patient referred by partner teams following a call for participation within the Neuro-Oncology Club and the Skull Base Club of the French Neurosurgery Society, recruited under the same procedure as the AMAVEA association.